Furthermore, recent studies have reported that (i) STAT3 inhibition can potentiate the antitumor activity of cisplatin [16]; (ii) inhibitor of Janus kinase 2 (JAK2) blocks STAT3 activation and, thus, overcome tamoxifen resistance [17]; and (iii) activation of STAT3 induces resistance to many targeted cancer therapies [18]. This evidence concerns the gene JAK2 and cancer.